| 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) A Ribas, J Chesney, GV Long, JM Kirkwood, R Dummer, I Puzanov, ... Annals of Oncology 32, S868-S869, 2021 | 43 | 2021 |
| 1092TiP Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02 R Dummer, GV Long, AC Pavlick, MA Postow, A Ribas, C Robert, ... Annals of Oncology 32, S903, 2021 | | 2021 |
| 1109P Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study L Si, X Zhang, Y Shu, H Pan, D Wu, J Liu, L Mao, X Wang, X Wen, Y Gu, ... Annals of Oncology 34, S668-S669, 2023 | | 2023 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| 383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody … P Fernandez-Penas, M Carlino, K Tsai, V Atkinson, M Shaheen, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 4 | 2021 |
| 426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma R Dummer, GV Long, A Pavlick, M Postow, A Ribas, C Robert, RA Scolyer, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 1 | 2020 |
| 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma G Long, R Dummer, D Johnson, O Michielin, S Martin-Algarra, S Treichel, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 31 | 2020 |
| 799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma … P Fernandez-Penas, M Carlino, K Tsai, V Atkinson, M Shaheen, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 9 | 2020 |
| A Duplication at Chromosome 11q12. 2-11q12. 3 is Associated with Spinocerebellar Ataxia Type 20 (SCA20) MA Knight, D Hernandez, SJ Diede, HG Dauwerse, I Rafferty, ... | | |
| A duplication at chromosome 11q12. 2–11q12. 3 is associated with spinocerebellar ataxia type 20 MA Knight, D Hernandez, SJ Diede, HG Dauwerse, I Rafferty, ... Human molecular genetics 17 (24), 3847-3853, 2008 | 79 | 2008 |
| A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265). GV Long, R Dummer, A Ribas, I Puzanov, O Michielin, AM Vanderwalde, ... Journal of Clinical Oncology 34 (15_suppl), TPS9598-TPS9598, 2016 | 7 | 2016 |
| A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151) L Si, X Zhang, Y Shu, H Pan, D Wu, J Liu, F Lou, L Mao, X Wang, X Wen, ... Translational oncology 12 (6), 828-835, 2019 | 111 | 2019 |
| Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... Cancer Research 79 (13_Supplement), CT188-CT188, 2019 | 10 | 2019 |
| ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients ADJ Pearson, C Rossig, G Lesa, SJ Diede, S Weiner, J Anderson, J Gray, ... European Journal of Cancer 127, 52-66, 2020 | 58 | 2020 |
| All things must end: telomere dynamics in yeast ML DuBois, SJ Diede, AE Stellwagen, DE Gottschling Cold Spring Harbor Symposia on Quantitative Biology 65, 281-296, 2000 | 5 | 2000 |
| An emerging toolkit for targeted cancer therapies 177 GB Mills, JD Brooks, EA Vucic, KL Thu, K Robison, LA Rybaczyk, R Chari, ... | | |
| Assessment of palindromes as platforms for DNA amplification in breast cancer J Guenthoer, SJ Diede, H Tanaka, X Chai, L Hsu, SJ Tapscott, PL Porter Genome research 22 (2), 232-245, 2012 | 34 | 2012 |
| Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review XL Tan, A Le, H Tang, M Brown, E Scherrer, J Han, R Jiang, SJ Diede, ... Cancers 14 (24), 6108, 2022 | 3 | 2022 |
| Comparison of duration of response vs conventional response rates and progression-free survival as efficacy end points in simulated immuno-oncology clinical trials C Hu, M Wang, C Wu, H Zhou, C Chen, S Diede JAMA Network Open 4 (5), e218175-e218175, 2021 | 16 | 2021 |
| Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors KL MacQuarrie, Z Yao, AP Fong, SJ Diede, ER Rudzinski, DS Hawkins, ... Molecular and cellular biology, 2013 | 79 | 2013 |
